ClinicalTrials.gg
CompletedNCT05111145Updated Jul 11, 2023Results posted

A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)

A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 24 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-07-11.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
86
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.

Enrollment
14th of 23
86 · median 120
Started
2022
with 3 others
Phase 3
19 of 23
none open now
Registered
16th of 23
by date
Lead sponsor
20 of 23
Vertex Pharmaceuticals Incorporated

Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 14th largest by enrollment, is one of 4 that started in 2022, is one of 19 in phase 3, and was the 16th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elexacaftor

elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing elexacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) in participants with CF who are 12 years of age or older.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Completed study drug treatment in parent study (VX19-445-117 [NCT04599465] or VX20-445-126 [NCT04969224]), or had study drug interruption(s) in parent study but completed study visits up to the last scheduled visit of the treatment period in the parent study

Key Exclusion Criteria:

  • History of drug intolerance in a parent study

Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    ELX/TEZ/IVA

    Participants received ELX 200 mg once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period for up to 36 weeks.

    Drug: ELX/TEZ/IVA · Drug: IVA

Interventions

  • DrugELX/TEZ/IVA

    Drug pages: Elexacaftor · Tezacaftor · Ivacaftor

    Fixed-dose combination tablets for oral administration.

    Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor

  • DrugIVA

    Tablets for oral administration.

    Also known as: VX-770, ivacaftor

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 36

07

Results

Posted Jul 11, 2023

Participant flow

Participant flow — Overall Study
MilestoneELX/TEZ/IVA
Started86
Completed0
Not completed86
Withdrew: Commercial drug is available for participant76
Withdrew: Participant enrolled in another qualified vertex study10

Outcome measures

PrimarySafety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 36
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsELX/TEZ/IVA
Participants with TEAEs61
Participants with SAEs4

Adverse events

Collected over Day 1 up to Week 36. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ELX/TEZ/IVA0/86 (0%)4/86 (4.7%)33/86 (38.4%)
Most frequent serious events
Most frequent serious events
EventELX/TEZ/IVA
Gastroenteritis viralInfections and infestations1/86
Alanine aminotransferase increasedInvestigations1/86
Aspartate aminotransferase increasedInvestigations1/86
MalnutritionMetabolism and nutrition disorders1/86
AnxietyPsychiatric disorders1/86
Most frequent other events
Most frequent other events
EventELX/TEZ/IVA
COVID-19Infections and infestations16/86
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations11/86
NasopharyngitisInfections and infestations9/86
Upper respiratory tract infectionInfections and infestations6/86

Baseline characteristics

Baseline data is based on the parent study baseline, which is defined as the most recent non-missing measurement collected before the first dose of study drug in the treatment period of parent studies. Baseline data is presented for participants who received at least 1 dose of study drug in this study

Age, Continuous
Age, Continuous(years)ELX/TEZ/IVA
Mean25.3 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)ELX/TEZ/IVA
Female37
Male49
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ELX/TEZ/IVA
White79
Black or African American0
Asian0
American Indian or Alaska Native0
Native Hawaiian or other Pacific Islander0
Other0
Not collected per local regulations7
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ELX/TEZ/IVA
Hispanic or Latino11
Not Hispanic or Latino68
Not collected per local regulations7
08

Study locations

24 sites
  • The Prince Charles Hospital
    Chermside, Australia
  • Alfred Hospital
    Melbourne, Australia
  • Institute for Respiratory Health
    Nedlands, Australia
  • Telethon Kids Institute
    Nedlands, Australia
  • The Royal Children's Hospital
    Parkville, Australia
  • Mater Adult Hospital
    South Brisbane, Australia
  • Queensland Children's Hospital
    South Brisbane, Australia
  • Cliniques Universitaires de Bruxelles Hopital Erasme
    Brussels, Belgium
  • Universitair Ziekenhuis Brussel - Campus Jette
    Brussels, Belgium
  • Universitair Ziekenhuis Gent
    Gent, Belgium
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, Belgium
  • University of Calgary Medical Clinic of the Foothills Medical Centre
    Calgary, Canada
  • Stollery Children's Hospital
    Edmonton, Canada
  • Queen Elizabeth II Health Sciences Center
    Halifax, Canada
  • Klinika Nemoci Plicnich a Tuberkulozy
    Brno, Czechia
  • Fakultni nemocnice v Motole
    Praha 5, Czechia
  • Hospital Saint Joan de Deu
    Barcelona, Spain
  • Hospital Universitari Vall d Hebron
    Barcelona, Spain
  • Hospital Universitari Vall d´Hebron Servicio de Broncoscopia
    Barcelona, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, Spain
  • Hospital Virgen de la Arrixaca
    Murcia, Spain
  • Corporacio Sanitaria Parc Tauli - Sabadell Hospital Universitari
    Sabadell, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Dec 2022, 11 months.

Results were first posted in Jul 2023, 6 months after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 11 months is below that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2021
First posted
Nov 8, 2021
StartActual
Jan 14, 2022
Primary completionActual
Dec 20, 2022
CompletionActual
Dec 20, 2022
Results first posted
Jul 11, 2023
Last update
Jul 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05111145
Responsible party
Sponsor
First posted
Nov 8, 2021
Start date
Jan 14, 2022
Primary completion
Dec 20, 2022
Completion
Dec 20, 2022
Results posted
Jul 11, 2023
Last update
Jul 11, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor

Start the discussion